Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

HIF-1—a big chapter in the cancer tale (CROSBI ID 254112)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Ajduković, Jasna HIF-1—a big chapter in the cancer tale // Experimental oncology, 38 (2016), 1; 9-12

Podaci o odgovornosti

Ajduković, Jasna

engleski

HIF-1—a big chapter in the cancer tale

Approximately 1.0–1.5% of the genome is transcriptionally regulated by hypoxia, and hypoxia- inducible factor (HIF)-1α is the transcription factor modulating many of these genes. Cancer cells are able to survive hypoxic environments and hypoxia itself can activate adaptive cellular responses that contribute to tumor progression. Many HIF-1α-mediated biological effects are beneficial for tumor progression, including metabolic shift toward glycolysis, inhibition of fatty acid β-oxidation, production of cellular reactive oxygen species and altering expression of tumor suppressor genes. HIF-1 promotes selective mitochondrial autophagy, resistance to T cell mediated lysis of cancer cells, induction of pluripotent cancer stem cells, epithelial-mesenchymal and epithelial-mesenchymal- endothelial transitions beneficial for tumor growth and progression, loss of E-cadherin. HIF-1 also induces production of signal molecules and cytokines by carcinoma-associated fibroblasts and upregulation of certain microRNAs important for cancer progression. This minireview focuses on the HIF-1 promoting role in tumor initiation and progression and HIF-1 targeting. HIF-1 pathway downregulation seems to be promising in future cancer treatment.

adaptive cellular response, cancer stemness, hypoxia, hypoxia-inducible factor 1, tumor progression

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

38 (1)

2016.

9-12

objavljeno

1812-9269

2312-8852

Povezanost rada

Farmacija, Temeljne medicinske znanosti

Indeksiranost